| Literature DB >> 36148674 |
Shinhye Kim1, Erica Sy Chuang1, Suzana Sabaiduc1, Romy Olsha2, Samantha E Kaweski1, Nathan Zelyas3, Jonathan B Gubbay4,2, Agatha N Jassem5,1, Hugues Charest6, Gaston De Serres7,8,6, James A Dickinson9, Danuta M Skowronski5,1.
Abstract
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.Entities:
Keywords: A(H3N2); Influenza; clade; observational study; test-negative design; vaccine effectiveness
Mesh:
Substances:
Year: 2022 PMID: 36148674 PMCID: PMC9511683 DOI: 10.2807/1560-7917.ES.2022.27.38.2200720
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X